Dong-A ST announced on the 4th that its US subsidiary NeuroBo Pharmaceuticals has applied to the US Food and Drug Administration (FDA) for a phase 2 clinical trial plan for NASH treatment candidate DA-1241. This clinical trial will be conducted for 16 weeks on 87 patients with NASH. It is a multicenter, randomized, double-blind, placebo-controlled, parallel-comparison clinical trial to confirm the efficacy and safety of DA-1241. NeuroBo plans to initiate phase 2 clinical trials for DA-1241 in the US within the third quarter of this year. The target study end date is the second half of 2024. DA-1241 is a first-in-class mechanism of action on GPR119. The possibility of developing it as a NASH treatment was confirmed in